Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
MALVERN, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company…
From Phase III Trials to Commercialization Partnerships, MindRank’s AI Drug Development Value Comes into Focus
TMX Group Equity Financing Statistics – September 2026
TMX Group Limited Announces Release Date for Q3 2026 Financial Results and Analyst Conference Call
GMG Announces 48% Increase in Energy Density, Doubling of Cycle Life and 94% Energy Efficiency for 6 Minute Fast Charge
DGTL Holdings Inc. Announces Failure-to-File Cease Trade Order